Bentley Pharmaceuticals Elects Two New Directors and Adjourns Annual Stockholders' Meeting EXETER, N.H., June 8 /PRNewswire-FirstCall/ -- Bentley Pharmaceuticals, Inc. (NYSE:BNT), a specialty pharmaceutical company focused on advanced drug-delivery technologies, which also manufactures and markets generic and branded products in Europe, announced today that stockholders elected two new members to three-year terms on Bentley's Board of Directors. Those elected to the Board are F. Ross Johnson, the Chairman and Chief Executive Officer of RJM Group and the former Chairman of RJR/Nabisco Inc., and Edward J. Robinson, the former President, Chief Operating Officer and Chief Financial Officer of Avon Products, Inc. James R. Murphy, Bentley's Chairman and CEO, commented, "We are pleased and privileged to welcome Messrs. Johnson and Robinson to our board. Their extensive experience will add further depth to our board of directors." After the election of the directors, the annual meeting of stockholders was adjourned to allow continued voting on proposals to amend and restate Bentley's restated certificate of incorporation, some of which have not yet received sufficient votes in favor. The adjourned meeting will reconvene to vote on the proposals to amend and restate Bentley's restated certificate of incorporation at 4:00 p.m. Eastern time on Friday, June 11, 2004 at Bentley's corporate headquarters located at Bentley Park, 2 Holland Way, Exeter, New Hampshire. Bentley Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on advanced drug delivery technologies and pharmaceutical products. Bentley's proprietary drug technologies enhance or facilitate the absorption of pharmaceutical compounds across various membranes. Bentley also manufactures and markets a growing portfolio of generic and branded pharmaceuticals in Europe for the treatment of cardiovascular, gastrointestinal, infectious and neurological diseases through its subsidiaries, Laboratorios Belmac, Laboratorios Davur and Laboratorios Rimafar; and manufactures and sells active pharmaceutical ingredients through its subsidiary, Bentley A.P.I. Copies of Bentley Pharmaceuticals' press releases and other information may be obtained through Bentley's web site at http://www.bentleypharm.com/. DATASOURCE: Bentley Pharmaceuticals, Inc. CONTACT: Michael D. Price, Vice President, Chief Financial Officer of Bentley Pharmaceuticals, Inc., +1-603-658-6100; or Jonathan Birt of Financial Dynamics, +1-212-850-5600, for Bentley Pharmaceuticals, Inc. Web site: http://www.bentleypharm.com/

Copyright